Cengild Medical Berhad First Quarter 2025 Earnings: EPS: RM0.005 (vs RM0.004 in 1Q 2024)

Cengild Medical Berhad (KLSE:CENGILD) First Quarter 2025 Results

Key Financial Results

• Revenue: RM22.3m (up 27% from 1Q 2024).
• Net income: RM4.00m (up 11% from 1Q 2024).
• Profit margin: 18% (down from 20% in 1Q 2024). The decrease in margin was driven by higher expenses.
• EPS: RM0.005 (up from RM0.004 in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cengild Medical Berhad shares are up 9.8% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Cengild Medical Berhad (at least 1 which is concerning), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.